A Novel Therapy for Urinary Tract Infections UTIs are the most common bacterial infections affecting 400 million people per year worldwide, with a treatment market is estimated at $9.89 billion. Up to 80% of UTIs are caused by uropathogenic E. coli that regularly form...
Advanced Antimicrobial Surface Testing Wirral SME, SafeClimb designs, manufactures and maintains height safety equipment, including safety ropes and harnesses, for industrial and leisure markets worldwide. Due to enhanced cleaning regimens adopted during the COVID-19...
Revolutionising Healthcare Cystic fibrosis (CF) is a genetic disease that affects around 11,000 people in the UK, and over 160,000 globally. One of the most important bugs that causes this is Pseudomonas aeruginosa – a bacterium that is present everywhere but rarely...
Combating antibiotic resistance Antibiotics are used to treat or prevent some types of bacterial infection. They are becoming less effective due to overuse in recent years. NBIC Research Fellow, Dr Callum Highmore, and researchers at the NIHR Southampton Biomedical...
Antimicrobial Discovery and Biobanking Workshop Report In collaboration with the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP) and Noguchi Memorial Institute for Medical Research (NMIMR) in Ghana, we organised a workshop on Antimicrobial...
